UPDATE - Mesoblast to Host Virtual Symposium With Key Opinion Leader Highlighting Acute Graft Versus Host Disease
Mesoblast Limited - American Depositary Shares (MESO)
US:NASDAQ Investor Relations:
investorsmedia.mesoblast.com
Company Research
Source: GlobeNewswire
NEW YORK and MELBOURNE, Australia, June 14, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ: MESO; ASX: MSB), global leader in cellular medicines for inflammatory diseases, today announced that it will host a virtual symposium on Monday, June 17 to discuss Mesoblast’s product candidate, remestemcel-L, in steroid refractory acute graft versus host disease (aGVHD) in children, and to include Dr. Susan E. Prockop, a key opinion leader with significant expertise and experience in treating pediatric patients with this life threatening disease. Dr. Prockop is a pediatric oncologist specializing in bone marrow and stem cell transplantation at Memorial Sloan Kettering Cancer Center in New York. She also served as an investigator in Mesoblast’s recent remestemecel-L study in pediatric patients with steroid refractory aGVHD. The webcast event will feature a presentation by Dr. Prockop who will address the current management and treatment options for patients with aGVHD. She will also dis
Show less
Read more
Impact Snapshot
Event Time:
MESO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MESO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MESO alerts
High impacting Mesoblast Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
MESO
News
- Three Leading Growth Companies In Australia With Insider Ownership Reaching 27% [Yahoo! Finance]Yahoo! Finance
- Degenerative Disc Disease Market Forecast - 2032; NSAIDs, Opioids, and others are major revenue generators [Yahoo! Finance]Yahoo! Finance
- Degenerative Disc Disease Drug Pipeline Research Report 2024 Featuring Spine BioPharma, Angitia Biopharmaceuticals, Mesoblast, BioRestorative Therapies, and DiscGenics, Inc. [Yahoo! Finance]Yahoo! Finance
- Mesoblast Limited: Back From The Dead [Seeking Alpha]Seeking Alpha
- Mesoblast Limited (NASDAQ: MESO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat